IRADIMED CORP — Form 8-K
Filed July 31, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Iradimed reported Q2 2026 revenue of $20.5M (up 0.5% YoY from $20.4M); Q2 GAAP diluted EPS $0.41, non-GAAP $0.46. Six-month revenue $42.4M (up 6% YoY); six-month GAAP EPS $0.86, non-GAAP $0.95. Declared regular quarterly dividend of $0.20/share payable August 28, 2026. Company reaffirmed full-year 2026 guidance: revenue $91–96M, GAAP EPS $1.90–$2.05, non-GAAP EPS $2.09–$2.24. Launching next-generation 3870 MRI IV pump (replacing 3860), with Q3 guidance $23–24.5M revenue.
Why this rating
Q2 near-flat YoY growth (0.5%) and margin compression (78%→74%) offset by solid H1 performance (+6% revenue, +5% net income) and product transition execution. Dividend sustainable; guidance unchanged. Small relative to $481M market cap.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.